Abbott Laboratories (ABT) Analysts See $0.73 EPS; THROMBOOGENICS NV (TBGNF) Shorts Down By 23.94%

Analysts expect Abbott Laboratories (NYSE:ABT) to report $0.73 EPS on January, 24 before the open.They anticipate $0.08 EPS change or 12.31% from last quarter’s $0.65 EPS. ABT’s profit would be $1.27 billion giving it 19.54 P/E if the $0.73 EPS is correct. After having $0.66 EPS previously, Abbott Laboratories’s analysts see 10.61% EPS growth. The stock decreased 0.68% or $0.39 during the last trading session, reaching $57.07. About 4.00 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 1, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

THROMBOOGENICS NV (OTCMKTS:TBGNF) had a decrease of 23.94% in short interest. TBGNF’s SI was 48,300 shares in January as released by FINRA. Its down 23.94% from 63,500 shares previously. It closed at $3.95 lastly. It is down 0.00% since January 1, 2017 and is . It has underperformed by 16.70% the S&P500.

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company has market cap of $113.19 million. The companyÂ’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It currently has negative earnings. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA.

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 15 have Buy rating, 0 Sell and 9 Hold. Therefore 63% are positive. Abbott Laboratories had 88 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Thursday, October 19 by Barclays Capital. The firm earned “Overweight” rating on Thursday, April 20 by Barclays Capital. Cowen & Co maintained the stock with “Buy” rating in Tuesday, August 15 report. Citigroup maintained it with “Neutral” rating and $5 target in Thursday, October 19 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Wells Fargo on Thursday, September 28. The firm earned “Buy” rating on Thursday, July 20 by Stifel Nicolaus. The rating was maintained by Jefferies with “Buy” on Tuesday, March 15. The company was maintained on Friday, July 21 by Gabelli. RBC Capital Markets maintained it with “Buy” rating and $60.0 target in Thursday, October 19 report. The stock has “Outperform” rating by RBC Capital Markets on Thursday, January 26.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dived, as 47 investors sold Abbott Laboratories shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Parallax Volatility Advisers L P holds 0.02% in Abbott Laboratories (NYSE:ABT) or 253,010 shares. 1.80 million were reported by Partner Fund Mgmt L P. Milestone Gp stated it has 0.04% in Abbott Laboratories (NYSE:ABT). 176,899 were reported by South Dakota Investment Council. Checchi Advisers Ltd Company has invested 0.07% of its portfolio in Abbott Laboratories (NYSE:ABT). Gould Asset Management Lc Ca holds 0.11% of its portfolio in Abbott Laboratories (NYSE:ABT) for 4,380 shares. The New York-based First Long Island Invsts Limited Liability Corp has invested 3.24% in Abbott Laboratories (NYSE:ABT). Comerica Secs Inc accumulated 64,118 shares. Peavine Capital Lc owns 21,600 shares. Eads & Heald Invest Counsel holds 31,178 shares or 1.03% of its portfolio. City Holdg has 0.91% invested in Abbott Laboratories (NYSE:ABT). Royal Fincl Bank Of Canada owns 4.23 million shares. New England Private Wealth Advsr Ltd Llc holds 0.17% or 10,678 shares in its portfolio. Lakeview Capital Prns Limited Liability has invested 0.24% in Abbott Laboratories (NYSE:ABT). Cedar Hill Assocs Lc, Illinois-based fund reported 19,465 shares.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $99.34 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 46.06 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

The post Abbott Laboratories (ABT) Analysts See $0.73 EPS; THROMBOOGENICS NV (TBGNF) Shorts Down By 23.94% appeared first on Stock Market News | HillCountryTimes | Get it Today.

from
https://www.hillcountrytimes.com/2018/01/01/abbott-laboratories-abt-analysts-see-0-73-eps-thromboogenics-nv-tbgnf-shorts-down-by-23-94/